People In The News: Changes At Impax, Isarna, Sorrento, Macrogenics
Actavis global R&D exec G. Frederick Wilkinson joins Impax as president and CEO; FDA veteran Shaw Chen moves to Polaris. On the government side, Senate HELP Cmte. Is slated to review Sylvia Burwell’s nomination for HHS secretary and Michael Hash is retiring from the department. More personnel announcements in this month’s column.
You may also be interested in...
European Notebook: Price Cuts Planned In France; IPO Window Thrown Open; European Big Pharmas Pursue Major Deals
Increased optimism about economic growth in Europe has been followed by IPOs becoming more common among the region’s biotech companies; there’s a speculation frenzy about M&A; and with European parliamentary elections in May, further regulatory and legislative changes are likely later in the year.
White House health reform operative Michael Hash will move to director of the HHS Office of Health Reform, succeeding Jeanne Lambrew.
Efficacy seen in reducing hospitalization in high-risk heart failure patients, but not in reducing the risk of cardiovascular death. Analysts say this portends a more niche opportunity for vericiguat.